Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344412 | 0.94 | MAPK14 (0.57) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2342385 | 0.91 | PKM (0.61) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2347606 | 0.91 | MAPK14 (0.55) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2352480 | 0.91 | PKM (0.70) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2341989 | 0.90 | MAPK14 (0.55) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2350602 | 0.90 | NAMPT (0.55) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2348622 | 0.90 | MAPK14 (0.54) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2349970 | 0.90 | MAPK14 (0.54) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2346273 | 0.89 | RAB9A (0.61) | MAPK14PKMMAPK1NPC1TP53 | |
| SCHEMBL2354124 | 0.89 | RAB9A (0.61) | MAPK14PKMMAPK1NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008303-B2 | e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | MAPK14 4315/4885PKM 4821/4885MAPK1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.